Intrahepatic Tumor Burden as a Novel Factor Influencing the Introduction of Second-line Chemotherapy for Hepatocellular Carcinoma

2020 ◽  
Vol 40 (7) ◽  
pp. 3953-3960 ◽  
Author(s):  
MICHIHISA MORIGUCHI ◽  
TAKESHI ARAMAKI ◽  
RUI SATO ◽  
KENJI IWAI ◽  
SATOSHI TSUCHIYA ◽  
...  
2015 ◽  
Vol 24 (3) ◽  
pp. 379-382
Author(s):  
Tadahisa Inoue ◽  
Hitoshi Sano ◽  
Takashi Mizushima ◽  
Hirotada Nishie ◽  
Hiroyasu Iwasaki ◽  
...  

We present the case of a Japanese man in his 60s with duodenal neuroendocrine carcinoma with distant metastases. Chemotherapy with irinotecan plus cisplatin was initiated as a first-line regimen. However, disease progression was observed after only two cycles. Therefore, amrubicin was administered as a second-line chemotherapy. The patient showed a long-term effect of amrubicin therapy, and the best response was a partial response after seven cycles. For duodenal neuroendocrine carcinoma, amrubicin therapy can be considered an effective treatment option as salvage chemotherapy.


2020 ◽  
Author(s):  
Angela Lamarca ◽  
Daniel Palmer ◽  
Harpreet Wasan ◽  
Paul J. Ross ◽  
Yuk Ting Ma ◽  
...  

2012 ◽  
Vol 69 (6) ◽  
pp. 1641-1645 ◽  
Author(s):  
Alberto Zaniboni ◽  
Enrico Aitini ◽  
Sandro Barni ◽  
Daris Ferrari ◽  
Stefano Cascinu ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document